Bangalore: Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity.
This is further to the Company's previous intimation of 27th March, 2024, informing that approval was received fromthe MHRA for Liraglutide (gVicotza), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.
Read also: Biocon obtains approval for diabetes drug Liraglutide in UK
"The approvals will further strengthen Biocon’s portfolio of vertically integrated, complex drug products," the Company stated.
Read also: Biocon Biologics secures US market entry date for Bmab 1200, a Proposed Biosimilar to Stelara
Biocon Limited, publicly listed in 2004, is an innovation-led global biopharmaceuticals company. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.
Read also: Eris Lifesciences acquires Biocon Biologics India branded formulation business for Rs 1242 crore